期刊文献+

PEG-重组酵母尿酸酶结合物的基本特性研究 被引量:3

Study on General Properties of PEGylated Recombinant Uricase
原文传递
导出
摘要 重组Candida utilis尿酸酶由含PET-Uricase表达质粒的重组E.coli JM109(DE3)经乳糖诱导表达,菌体破碎后依次经过硫酸铵沉淀、阴离子交换层析和凝胶过滤层析可以获得纯度95%的重组尿酸酶。还原性SDS-PAGE和HPLC测得其亚基表观分子量和天然分子量分别约为33kDa和130kDa。获得的纯酶与20kDa(mPEG)2-Lys-NHS在特定的条件下反应合成PEG-重组酵母尿酸酶结合物,考察了重组酵母尿酸酶PEG化前后的基本性质,结果显示PEG化尿酸酶的最适pH为7.5,较修饰前下降了1个pH单位,酸碱稳定范围与修饰前类似,都在pH6~10范围内稳定;修饰前后最适温度均为40℃,重组酵母尿酸酶的热稳定性和抗蛋白酶水解能力较PEG修饰前有较大提高;PEG化尿酸酶可保留修饰前酶活力的87.5%;在最适条件下,PEG-尿酸酶结合物的Km为3.57×10-5mol/L,而修饰前测得的Km为3.91×10-5mol/L。研究结果为深入探讨PEG化尿酸酶的结构与功能奠定了基础。 Induced by lactose, the recombinant Candida utilis uricase was expressed in the E. coli JM109 (DE3) that carried the PET-uricase expression plasmid. The crude extraction was processed by the following purification procedures including ammonium sulfate precipitation, anion-exchange chromatography and gel filtration chromatography and the recombinant uricase with 95% purity could be obtained. Using HPLC and reduced SDS-PAGE, the native molecular weight of this enzyme and the apparent molecular weight of its subunit were determinied as 130 kDa and 33 kDa. The (mPEG)2-Lys-NHS of 20 kDa was used to modify the purified uricase and the study on zymological properties of uricase before and after modification was carried on. The results showed that the optimum pH of PEG modified uricase and native uricase were pH 7.5 and pH 8.5 respectively and both of them had good pH-stability from pH 6 to 10; both of the two had the same optimum temperature of 40℃, but the thermal stability and the ability of antitrypsin hydrolysis of the pegylated enzyme were much better than those of native enzyme ; the modified uricase retained 87.5% of the enzymatic activity of native uricase; under each optimum condition, the determined Km of uricase before and after pegylation were 3.91 × 10 ^-5 mol/L and 3.57 × 10^ -5 mol/L respectively. These findings may provide some information for deep investigation of structure and function of pegylated uricase.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2009年第11期23-28,共6页 China Biotechnology
基金 四川省教育厅资助项目(08ZB043)
关键词 CANDIDA utilis 尿酸酶 PEG化尿酸酶 蛋白质化学修饰 Candida utilis Uricase Pegylated uricase Chemical modification of protein
  • 相关文献

参考文献10

  • 1Oda M, Satta Y, Takenaka O, et al. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol,2002, 19(5): 640 -653.
  • 2Baeksgaard L, Sorensen J B. Acute tumor lysis syndrome in solid tumors-a case report and review of the literature. Cancer Chemother Pharmacol, 2003, 51 (3) : 187 - 192.
  • 3Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine, 2004, 71 (6) : 481 - 485.
  • 4Nuki G. Treatment of crystal arthropathy-history and advances. Rheum Dis Clin North Am, 2006, 32(2) : 333 -357.
  • 5才蕾,高向东,朱姝,王华,姚文兵.聚乙二醇修饰尿酸酶的研究(英文)[J].中国药科大学学报,2008,39(6):557-562. 被引量:7
  • 6Toyobo co. lid. Toyobo enzymes. Japan: Biochemical operations department, 1996. 171.
  • 7汪家政 范明.蛋白质技术手册[M].北京:科学出版社,2002(第一版).51-54.
  • 8Bomalaski J S, Hohsberg F W, Ensor C M, et al. Uricase formulated with polyethylene glycol ( uricase-PEG 20 ) : biochemical rationale and preclinical studies. J Rheumatol, 2002, 29(9) : 1942 - 1949.
  • 9Liao F, Zhu X Y, Wang Y M, et al. The comparison of the estimation of enzyme kinetic parameters by fitting reaction curve to the integrated Michaelis-Menten rate equations of different predictor variables. J Biochem Biophys Methods, 2005, 62( 1 ): 13 -24.
  • 10Davis S, Park Y K, Abuchowski A, et al. Hypouricaemic effect of polyethyleneglycol modified urate oxidase. Lancet, 1981, 2 (8241) : 281 -283.

二级参考文献11

  • 1Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol [ J ]. Joint Bone Spine, 2004,71 ( 6 ) : 481 - 485.
  • 2Nuki G. Treatment of crystal arthropathy--history and advances [ J]. Rheum Dis Clin North Am,2006,32 (2) :333 -357.
  • 3Brogard JM, Coumams D, Frankhauser J, et al. Enzymatic uricoly- sis : a study of the effect of a fungal urate-oxydase [ J ]. Rev Eur Etud Clin Biol, 1972,17 (9) : 890 - 895.
  • 4Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects[ J ]. Clin Ther, 2002,24 (11 ) : 1 720-1 740.
  • 5Roberts M J, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation [ J ]. Adv Drug Deliver Rev ,2002 ,54 (4) : 459 - 476.
  • 6Greenwald RB, Choe YH, McGuire J, et al. Effective drug delivery by PEGylated drug conjugates [ J ]. Adv Drug Deliver Rev,2003, 55(2) :217 -250.
  • 7Veronese FM, Pasut G. PEGylation, successful approach to drug delivery [ J ]. Drug Discov Today,2005,10 ( 21 ) : 1 451 - 1 458.
  • 8Robert H, Chen L, Abuchowski A, et al. Properties of two urate oxidases modified by the covalent attachment of poly (ethylene glycol) [ J ]. Biochim Biophys Acta, 1981,660 ( 2 ) : 293 - 298.
  • 9Davis S, Park YK. Abuchowski A, et al. Hypouricaemic effect of polyethylene glycol modified urate oxidase [ J ]. Lancet, 1981,2 (8 241) :281 -283.
  • 10Gong XW, Wei DZ, He ML, et al. Discarded free PEG-based assay for obtaining the modification extent of pegylated proteins [ J]. Talanta,2007,71 ( 1 ) :381 - 384.

共引文献67

同被引文献20

  • 1Song-shanTANG,Juan-huiZHANG,Ming-huaDU,JieWU,Jing-jingLIU.Construction and activity of a novel GHRH analog, Pro-Pro-hGHRH(1-44)-Gly-Gly-Cys[J].Acta Pharmacologica Sinica,2004,25(11):1464-1470. 被引量:6
  • 2方卫纲,黄晓明,王玉,陈伟,朱卫国,陈嘉林,曾学军.北京地区部分人群痛风的流行病学调查[J].基础医学与临床,2006,26(7):781-785. 被引量:48
  • 3王楠,赵洪亮,刘志敏,刘党生,薛冲,熊向华.生长激素释放激素和人血清白蛋白融合蛋白的克隆表达[J].生物技术通讯,2007,18(4):574-577. 被引量:4
  • 4Suzuki K, SAKASEGAWA S I. Molecular Cloning and expression of uricase gene from Arthrobacter globiformis in Escherichia coli and characterization of the gene prod- uct[J]. Journal of Bioscience and Bioengineering, 2004, 3(98): 153-158.
  • 5Friedman T B,Barker A P. Purification and partial charac- terization of urate oxidase from Drosophila melanogaster[J]. Insect Biochem, 1982, 5(12): 563-570.
  • 6Liu C Y, McCallum R P, Schiffer C A.A single dose of rasburicase is sufficient for the treatment of hypenn-icemia in patients receviing chemotherapy[J].Leukemia Research, 2005(29): 463-465.
  • 7Terkeltaub R. Update on gout: new therapeutic strategies and options[J].R_heumatology,2010,6:30-35.
  • 8Oda M, Satta Y. Loss of urate oxidase activity in homi- noids and its implications[J]. Mol Biol Evol, 2002, 19(5): 640-53.
  • 9Li J M, Chen Z, Hou L H. High-level expression, puri- fication and characterization of non-tagged Aspergillus Xavus urate oxidase in Escherichia coli[J]. Protein Ex- pression and Purification, 2006, 49: 55-59.
  • 10Bardin T. Current management of gout in patients unre- sponsive or Allergic to allopurinol[J]. Joint Bone Spine, 2004, 71(6): 481-485.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部